Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356935 | 0.94 | MMP2 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7788422 | 0.87 | GAA (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7788424 | 0.87 | GAA (0.49) | CA1CA2CA9CA12CA7 | |
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.84 | CA12 (0.63) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16805852 | 0.84 | NPC1 (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10452305 | 0.83 | MMP2 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2364296 | 0.83 | MAPT (0.49) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2831629 | 0.83 | MAPT (0.49) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10451577 | 0.82 | ALDH1A1 (0.39) | CA1CA2CA9CA12CA7 | |
| 4-Cyanophenol SCHEMBL28947740 | 0.81 | ALDH1A1 (0.50) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444556-A | Preparation method of organosilicon intermediate 4-benzonitrile oxyalkyl trialkoxy silane | 苏州威迈芯材半导体有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-0545409-B1 | Liquid crystals with end groups containing more than one silane group | CONSORTIUM ELEKTROCHEM IND (DE) | 1996-03-06 | — | — | EP | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| EP-0654032-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS. | ZENECA LTD (GB) | 1995-05-24 | — | — | EP | disclosed |
| US-5399290-A | Liquid crystals with (polysila) alkyl wing groups | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1995-03-21 | — | — | US | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| EP-0545409-A1 | Liquid crystals with end groups containing more than one silane group | Consortium für elektrochemische Industrie GmbH (DE) | 1993-06-09 | — | — | EP | disclosed |
| EP-0193853-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4783462-A | 3(2H)pyridazinone, and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0193853-A2 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | CA1 4884/4885CA2 4833/4885CA9 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.